About US
Contact us
-
GlycoMimetics and Pfizer to further develop GMI-1070GlycoMimetics has entered into an exclusive worldwide licensing agreement with Pfizer for the advancement of GlycoMimetics' investigational compound, GMI-1070. GMI-1070, a pan-selectin inhibitor, is2011/10/17
-
Achievement of pre-clinical milestone triggers $4M payment from GSK to EpizymeEpizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients, today announced the achievement of pre-clinical milestones in its a2011/10/17
-
India to tighten scrutiny over foreign pharmaceutical takeoversIndia will tighten scrutiny over foreign takeovers of Indian pharmaceutical firms as part of discussions meant to ease concerns over the domestic drug industry in the country. From now, "brownfield2011/10/14
-
FDA clears Merck type 2 diabetes medicationThe US Food and Drug Administration (FDA) has approved Merck's Juvisync, a once-daily therapy for type 2 diabetes that combines glucose-lowering medication sitagliptin, the active component of Januvia2011/10/14
-
Meet Roquette at CPHI FrankfurtRoquette is a long-established supplier of actives and excipients to the pharmaceutical and cosmetics industries. Our new slogan "Simply formulate your wishes" points to the many services we offer and2011/10/14
-
Vitamin D plays an essential role in the body's fight against TBNot just important for building strong bones, an international team of scientists has found that vitamin D also plays an essential role in the body's fight against infections such as tuberculosis.2011/10/14
-
NovaSterilis awarded patent for sterilization process for pharmaceutical API using supercritical carbon dioxideNovaSterilis Inc., a developer of supercritical carbon dioxide technology, has been granted US Patent 8,012,414 B2. The patent, dated September 6, 2011 entitled “Sterilization of Drugs Using Supercrit2011/10/12
-
AstraZeneca to cut 400 US jobsAstraZeneca plans to cut 400 jobs in efforts to "streamline portions of its US commercial business." The job losses are planned for the company's US base in Delaware, although 70 of the 400 cuts will2011/10/12
-
FDA clears Merck type 2 diabetes medicationThe US Food and Drug Administration (FDA) has approved Merck's Juvisync, a once-daily therapy for type 2 diabetes that combines glucose-lowering medication sitagliptin, the active component of Januvia2011/10/12
-
AstraZeneca Faslodex wins Japanese regulatory approvalAstraZeneca has received Japanese regulatory approval for Faslodex (fulvestrant) 500mg, an oestrogen receptor antagonist for the treatment of postmenopausal women with hormone receptor-positive metast2011/9/30